RGEN News and Press, Repligen Corporation From 05/18/22

There's no way to sugarcoat it -- 2022 has been a rough time for the market. It seems that the decline has hit all sectors and all kinds of stocks. One sector that has been hit particularly hard is healthcare , down more than 11% year to date. As painful as that can be for sharehol...

Biopharmaceutical stocks have undergone a dramatic correction over the past six months, with the XBI declining by 45%. The decline was appropriate, given the number of companies that went public in 2021 with preclinical data and a valuation exceeding $1 billion. Not only would the...

Last summer I first covered Repligen, a company that develops tools and services for manufacturing biologics. While bad timing in regards to short-term performance, I reiterate my Strong Buy view of the company due to overall company strength. This article will update financial me...

Repligen makes equipment for the biologic drug manufacturing industry. RGEN's main products are focused on filtration, chromatography, process analytics products, and select proteins. Growth has not come at the expense of margins or ROIC. For further details see: LRT Cap...

LRT Capital is a fundamental investment hedge fund. We invest only in companies with durable competitive advantages, i.e. “moats.”. LRT Economic Moat strategy had a very strong month, and we are very optimistic about the year ahead. Many of our portfolio companies ar...

Repligen Corporation (RGEN) Q1 2022 Results Earnings Conference Call April 27, 2022, 08:30 AM ET Company Participants Sondra Newman - Vice President and Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call P...

Shares of biotech company Repligen (NASDAQ: RGEN) are up an impressive 10.1% as of 11:15 a.m. ET Wednesday, according to data from S&P Global Market Intelligence . The rally is in response to the release of quarterly sales and earnings figures that both topped analysts' expe...

Shares of Repligen (NASDAQ:RGEN) are trading 9.9% higher at $156.66 in morning trade on Wednesday, after the life sciences company reported Q1 2022 earnings that beat expectations. RGEN reported Q1 non-GAAP EPS of $0.92, which beat estimates by $0.20, and revenue of $206.4M, which beat estima...

Gainers: Nutex Health (NUTX) +24%. Repligen (RGEN) +14%. Zentalis Pharmaceuticals (ZNTL) +14%. Alkermes (ALKS) +12%. Clever Leaves (CLVR) +8%. Losers: Molecular Partners (MOLN) -37%. Agile Therapeutics (AGRX) -28%. Immunome (IMNM) -1...

Repligen press release (NASDAQ:RGEN): Q1 Non-GAAP EPS of $0.92 beats by $0.20. Revenue of $206.4M (+44.5% Y/Y) beats by $20.92M. GAAP gross margin was 60.1%, an increase of 190 bps; Adjusted (non-GAAP) gross margin was 60.4%, an increase of 100 bps. GAAP operating margin was 29.1%, an increas...